GALACTIC-HF Subgroup Analysis: Omecamtiv Mecarbil Effective Across Ethnic Groups

Published: 23 Sep 2021

  • Views:

    Views Icon 269
  • Likes:

    Heart Icon 0
Average (ratings)
No ratings
Your rating

In this video, Professor David Lanfear (Henry Ford Hospital, Detroit, MI, US) discusses a subgroup analysis of GALACTIC-HF which aimed to evaluate the effect of omecamtiv mecarbil in black patients with heart failure (HF) with reduced ejection fraction (HFrEF). Originally presented at HFSA 2021, the additional results suggest that the outcomes in black patients treated with this drug are similar to those in the overall population of the trial and white patients, showing the drug is effective and safe to use across ethnic groups. 


Discussion Points:

Importance of this subgroup analysis
Study design and patient population
Key findings 
Impact on practice and further research
Take-home messages


Recorded Remotely from Detroit, 2021.
Interviewer: Jordan Rance